These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31661152)

  • 1. Mutations and the Importance of Genetic Testing.
    Kurian AW
    Oncology (Williston Park); 2019 Oct; 33(10):. PubMed ID: 31661152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
    Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-based Genetic Testing for Precision Prevention.
    Evans O; Manchanda R
    Cancer Prev Res (Phila); 2020 Aug; 13(8):643-648. PubMed ID: 32409595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of genetic testing for inherited breast and ovarian cancer risk.
    Calzone KA
    Nurs Spectr (Wash D C); 1998 Nov; 8(23):12-4. PubMed ID: 10542772
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hereditary breast and ovarian cancer - indications for genetic testing, counseling and options for mutation carriers].
    Bürki N
    Ther Umsch; 2010 Jul; 67(7):359-66. PubMed ID: 20577964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding hereditary breast and ovarian cancer.
    Roesser KA
    Clin J Oncol Nurs; 2003; 7(5):591-4. PubMed ID: 14603558
    [No Abstract]   [Full Text] [Related]  

  • 9. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
    Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
    Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new paradigm of genetic testing for hereditary breast/ovarian cancers.
    Kwong A; Chen JW; Shin VY
    Hong Kong Med J; 2016 Apr; 22(2):171-7. PubMed ID: 26980575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.
    Fayanju OM; Park KU; Lucci A
    Ann Surg Oncol; 2018 Feb; 25(2):512-519. PubMed ID: 29159748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based genetic testing for Women's cancer prevention.
    Evans O; Gaba F; Manchanda R
    Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():139-153. PubMed ID: 32245629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of Multigene Testing: Catching the Train That's Left the Station.
    Swisher EM
    JAMA Oncol; 2015 Oct; 1(7):951-2. PubMed ID: 26270409
    [No Abstract]   [Full Text] [Related]  

  • 15. BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia.
    Mundhofir FE; Wulandari CE; Prajoko YW; Winarni TI
    Asian Pac J Cancer Prev; 2016; 17(3):1539-46. PubMed ID: 27039803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
    Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
    Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability in Cancer Risk with BRCA Mutations.
    Cancer Discov; 2015 Jul; 5(7):OF16. PubMed ID: 25952264
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic/familial high-risk assessment: breast and ovarian.
    Daly MB; Axilbund JE; Buys S; Crawford B; Farrell CD; Friedman S; Garber JE; Goorha S; Gruber SB; Hampel H; Kaklamani V; Kohlmann W; Kurian A; Litton J; Marcom PK; Nussbaum R; Offit K; Pal T; Pasche B; Pilarski R; Reiser G; Shannon KM; Smith JR; Swisher E; Weitzel JN;
    J Natl Compr Canc Netw; 2010 May; 8(5):562-94. PubMed ID: 20495085
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.